Get started
Author

Runhui Zheng

Observed names: RunHui Zheng, Zheng Runhui
ORCID: 0009-0003-3682-1046
Observed ORCIDs: 0009-0003-3682-1046, 0000-0001-7515-1637
OpenAlex ID: A5076676236
Targeted delivery and controlled release of Paclitaxel for the treatment of lung cancer using single-walled carbon nanotubes
2016 · Baodan Yu, Li Tan, et al. · Materials Science and Engineering C · 66
PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow
2021 · Ling Xu, Lian Liu, et al. · Frontiers in Oncology · 39
PDF
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU
2021 · Runhui Zheng, Jing Zhou, et al. · Experimental Hematology and Oncology · 19
PDF
Targeting ferroptosis in cancer therapy: Mechanisms, strategies, and clinical applications
2025 · Zhangshuai Dai, Jinyi Liu, et al. · Cell investigation. · 16
Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia
2020 · Danlin Yao, Ling Xu, et al. · BioMed Research International · 15
PDF
Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer
2017 · Baodan Yu, Junli Wang, et al. · Experimental and Therapeutic Medicine · 14
PDF
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion
2020 · Runhui Zheng, Xiaobo Chen, et al. · Case Reports in Hematology · 12
PDF
The establishment of a cytomegalovirus -specific CD8+ T-cell threshold by kinetic modeling for the prediction of post-hemopoietic stem cell transplant reactivation
2022 · Jing Zhang, Jinpeng Cao, et al. · iScience · 8
The Platelet Isoform of Phosphofructokinase in Acute Myeloid Leukemia: Clinical Relevance and Prognostic Implication
2018 · Xiaodan Luo, Dantian Zheng, et al. · Blood · 8
Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes
2014 · GanLin He, ChunYan Wang, et al. · Cancer Cell International · 8
PDF
Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial
2025 · Qihua Zou, Yuchen Zhang, et al. · Cancer Medicine · 6
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation
2015 · Runhui Zheng, Bailu Xie, et al. · Annals of Hematology · 5
A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma
2025 · Hua Wang, Demei Feng, et al. · BMC Cancer · 3
Oncogenic Potential of Epstein‐Barr Virus in NK and NKT Cells Contribute to the Rapid Deterioration of Hemophagocytic Lymphohistiocytosis
2025 · Tingting Cui, Mingzhu Huang, et al. · Journal of Medical Virology · 2
PDF
Multi-omics analysis unraveling stemness features associated with oncogenic dedifferentiation in 12 cancers
2025 · Jun Cheng, Jiafan Cao, et al. · Cancer Letters · 2
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
2024 · Xiaodan Luo, Ao Chen, et al. · Frontiers in Immunology · 2
PDF
Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial
2025 · Qingqing Cai, Yi Xia, et al. · Blood · 1
PDF
ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China
2023 · Jianyu Weng, Xin Huang, et al. · Blood · 1
Oncogenicity of EBV-infected natural killer T cells deteriorate EBV-related hemophagocytic lymphohistiocytosis
2022 · Tingting Cui, Mingzhu Huang, et al. · Research Square · 1
PDF
Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma
2026 · Lingchao Shi, Le Qin, et al. · Molecular Cancer Therapeutics
Immune dysregulation and exhaustion in EBV- associated hemophagocytic lymphohistiocytosis: insights from single-cell transcriptomics and TCR repertoire analysis
2026 · Xiaodan Luo, Ao Chen, et al. · Frontiers in Immunology
PDF
POSTER: ALL-741: Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study
2026 · Kezhi Huang, Yiqing Li, et al. · Clinical Lymphoma Myeloma & Leukemia
ALL-741: Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study
2026 · Kezhi Huang, Yiqing Li, et al. · Clinical Lymphoma Myeloma & Leukemia
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial
2026 · Qihua Zou, Shenrui Bai, et al. · Nature Communications
PDF
Zanubrutinib plus rituximab as front-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma: A single-arm, phase II study (ZAMA).
2026 · Yi Xia, Qingqing Cai, et al. · Journal of Clinical Oncology
PDF
Works count: 46
Citation count: 228
H-index: 8
I10-index: 7
Year
Topic
Type